Arcellx, Inc.
ACLX
Rankning i aktier
#2739
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Aktiekurs
$115.07
Senast synkroniserad: 2026-05-15
Marknadsvärde
$6.73B
Förändring (1 dag)
0.00%
Förändring (1 år)
38.04%
Land
US
Handel Arcellx, Inc. (ACLX)
Kategori
Healthcare
Aktiekurshistorik för Arcellx, Inc. (ACLX)
Högsta slutkurs: $115.07 den 2026-05-01
Lägsta slutkurs: $17.58 den 2022-02-01
Lägsta slutkurs: $17.58 den 2022-02-01
Aktiekurshistorik för Arcellx, Inc. från 2022 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2026 (TTM) | 30.35% |
| 2025 | -17.00% |
| 2024 | 52.40% |
| 2023 | 93.55% |
| 2022 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
